REGENXBIO Inc. (RGNX) · Aug 24, 2026 · Other events

REGENXBIO’s RGX-121 hits a new FDA hold, derailing near-term BLA hopes

BLA delay — No near-term resubmission after a planned Q3 2026 filing

Five asymptomatic spine findings trigger an FDA hold and push RGX-121’s resubmission beyond the previously expected third quarter.

The update breaks a near-term regulatory expectation. Before this filing, the standing plan was to resubmit the RGX-121 BLA in the third quarter of 2026; the company now says it does not expect to resubmit in the near term. That is a meaningful timeline reset, not a routine confirmation of the prior clinical hold situation.

The trigger is five previously treated patients with asymptomatic spine MRI findings. The findings were small nodules or cystic masses detected through expanded monitoring in participants treated roughly three to six years ago, while no brain nodules or masses were found. (Regulatory update) 〔0〕

The company’s reassuring clinical framing does not remove the regulatory problem. All five participants remain clinically stable or improved, and investigators consider the findings nonserious and likely benign, but the filing also acknowledges that their nature and causation are unconfirmed. (Regulatory update) 〔1〕 Because the FDA has imposed a clinical hold and the company is waiting for the full hold letter, the key uncertainty is now whether RGX-121 can support an eventual resubmission at all—and on what additional evidence or timeline.

Net read: materially worse than the market’s prior setup for RGX-121. The Duchenne BLA submission and wet-AMD data remain identified as upcoming catalysts, but those programs do not offset the immediate loss of the MPS II regulatory path. (Regulatory update) 〔2〕

What to watch next

Full FDA clinical hold letter and additional patient imaging

Original filing on SEC EDGAR

More REGENXBIO Inc. news

REGENXBIO’s RGX-121 hits a new FDA hold, derailing near-term BLA hopes | RGNX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.